series-c-plus
Stage
1
Investors
About
Castle Biosciences develops and commercializes molecular diagnostic tests using genomic and proteomic technologies to provide risk stratification and clinical decision support for patients with skin cancers and other malignancies such as melanoma, squamous cell carcinoma, uveal melanoma, and Barrett's esophagus.
Explore Castle Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.